Cell and gene manufacturing: a case study approach to overcoming challenges

Cell & Gene Therapy Insights 2021; 7(3), 393

10.18609/cgti.2021.065

Published: 29 April 2021
FastFacts
Sean Werner

As cell therapy manufacturing moves from translational research to industrial scale-out, Sexton Biotechnologies spoke to competitors, customers, and collaborators to better understand the current challenges.  

Watch the video or read the poster to learn:

  • What are the biggest hurdles for cell and gene therapies?
  • What are the challenges with current technologies and manufacturing methods?
  • What are the biggest payoffs of solving these problems?

About the speaker

Sean Werner, President, Sexton Biotechnologies. A manufacturer or processing and handling tools and reagents for the development and manufacture of cell and gene therapies. Sean received his PhD from Purdue University in Biology followed by post- doctoral positions at the Indiana University School of Medicine and Eli Lilly. Prior to his current role he spent 11 years with Cook Medical and Cook Regentec filling various roles in the global regulatory and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. In his 15 years working in the life science industry, he has guided pre-clinical and clinical testing and submission strategies leading to global commercialization of multiple medical devices and bioprocessing tools.